Letroblock® 2,5 mg

Description

Indications

The drug is indicated for the treatment of

• Early-stage invasive breast cancer, whose cells have hormone receptors, in postmenopausal women as adjuvant therapy.
• Early stage invasive breast cancer in postmenopausal women after completion of standard adjuvant therapy with tamoxifen for 5 years as extended adjuvant therapy.
• Common hormone-dependent forms of breast cancer in postmenopausal women (first-line therapy).
• Disseminated forms of breast cancer with disease recurrence or progression in postmenopausal women (natural or induced) who have received prior anti-estrogen therapy.
• Hormone-dependent HER-2 negative breast cancer in postmenopausal women as neoadjuvant therapy when chemotherapy is contraindicated and emergency surgery is not required.

Contraindications

• Hypersensitivity to letrozole or any of the other components of the drug.
• Endocrine condition specific to the reproductive period.
• Pregnancy, lactation period.
• Age below 18 years.